Longstanding claims that one of the reasons for high drug prices in the US is the actions of pharmacy benefit management ... investigated by the Federal Trade Commission (FTC).
Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen as the agency’s first report, but draws on more data.
The Federal Trade Commission has released its second report digging into how the business practices of pharmacy benefit managers ... The Pharmaceutical Care Management Association, the largest ...
FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging, PBMs, UnitedHealth OptumRx, CVS Caremark Rx, Express Scripts ...
I'm an antitrust expert and former FTC ... benefits of PBM activities may be quite substantial. In a July 2022 National Bureau of Economic Research working paper, The Value of Pharmacy Benefits ...
The largest pharmacy-benefit managers hiked ... vice president of the Pharmaceutical Care Management Association, a trade association representing PBMs. The FTC analyzed data submitted by the ...
Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...
The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...
The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.
For a moment, it looked like Congress would actually enact reforms of controversial pharmacy benefit managers ... to curb PBMs’ practices. The Federal Trade Commission in September sued the ...